Global Mid Pharma Licensing and M&A Trends Analysis Report 2011-2016: The Top Deal-Makers by Volume were Merck KGaA and Celgene

Dublin, May 24, 2017 -- Research and Markets has announced the addition of the "Mid Pharma Licensing and M&A Trends, 2011-16" report to their offering.

Between Q1 2011 and Q3 2016, the nine-company Mid Pharma cohort was responsible for around $200bn in up-front mergers and acquisitions (M&A) value and $10bn in up-front licensing value, driving deal volume and deal value in the biopharmaceutical sector.

The total number of alliances peaked in 2014, whereas the up-front value attached to these alliances peaked in 2015. M&A volume has increased every year since 2011, and up-front M&A value peaked in 2015.

The Mid Pharma group signed more than 300 alliance deals, from discovery through to marketed assets, and inked 50 acquisitions during the nearly six-year timeframe. For alliances, the top deal-makers by volume were Merck KGaA and Celgene; in terms of value, Celgene was by far the biggest spender on up-front alliance payments. For M&A, the top buyers were Allergan and Shire (by volume and by value).

Among therapeutic categories, oncology held the top spot in both alliance volume and alliance value. For M&A, there were more acquisitions driven by immunology and inflammation assets than any other therapeutic category. Acquisitions during the period broke multiple records, including the largest-ever biotech acquisition premium and the most money paid for a clinical-stage biotech. However, M&A value was driven by a small handful of large deals in which the target companies' product portfolios and pipelines were diversified across several therapeutic areas.

The majority of alliances focused on technologies and product candidates in early-stage development (discovery or preclinical stage), whereas those companies most likely to be acquired by Mid Pharma members had lead assets on the market or in Phase II development.

Key Topics Covered:

1. Executive Summary

2. Mid Pharma Peer Set Overview

• Ownership and structure
• Geography
• Mid Pharma boasts a strong R&D track record
• Mid Pharma companies still rely on business development for growth
• Size and scope

2. Trends in Alliance and M&A Volume and Value

• Alliance volume and value trends
• M&A volume and value trends

3. Therapeutic Area Breakdown Trends

• Alliance therapeutic area trends
• M&A therapeutic area trends

4. Clinical Stage Breakdown Trends

• Alliance clinical stage trends
• M&A clinical stage trends

5. Mid Pharma Out-Licensing Trends

• Mid Pharma out-licensing value is highly concentrated
• Out-licensing to halve risk and expense
• Spin-offs offer a broad range of deals

6. Mid Pharma Option-Based Deal Trends

• Buyout options exercised
• Options are getting more expensive

7. Mid Pharma Company Case Studies

• Celgene is Mid Pharma's biotech alliance leader
• Allergan's interest in biotech M&A blooms late
• Merck KGaA and UCB ally most often with academic institutions

8. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/t6l6cb/mid_pharma

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Pharmaceuticals